Clinical Trial Search

Phase 3 N=222 Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients

Renal Transplantation

Primary: Number of Participants With the Occurrence of Treatment Failures at 6 Months Post-transplantation — 20; 16 Number of participants

Novartis Results Feb 2011 63.5% serious AE View details

Phase 3 N=1,468 Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Primary: Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8) — -13.5; -16.5; -12.6; -17.0 mm Hg

Novartis Pharmaceuticals Results Feb 2011 0.3% serious AE View details

Phase 3 N=365 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Rhinitis, Allergic, Perennial · Allergic Rhinitis

Primary: Mean Change From Baseline Over the Entire Treatment Period in the Daily Reflective Total Nasal Symptom Score (rTNSS) — -4.226; -2.728 Points on a scale — p=<0.0001

GlaxoSmithKline Results Feb 2011 0.0% serious AE View details

Phase 3 N=741 NNRTI vs PI Regimens for HIV Infected Women After They Have Taken Nevirapine to Prevent Mother-To-Child HIV Transmission

HIV Infections

Primary: Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry — 12; 60; 12; 84 weeks — p=<0.001

Advancing Clinical Therapeutics Globally for… Results Feb 2011 8.1% serious AE View details

Phase 3 N=240 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Glioblastoma Multiforme · Astrocytoma

Primary: Percentage of Participants With Progression Free Survival (PFS) During the Study Duration — 5.3; 6.6; 2.1; 2.1 Percentage of Participants

Novartis Pharmaceuticals Results Feb 2011 49.5% serious AE View details

Phase 3 N=206 Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

Human Immunodeficiency Virus Infection

Primary: Percentage of Participants Responding (Plasma HIV-1 Ribonucleic Acid [RNA] Levels Less Than 40 Copies/Milliliter [mL]) at Week 48 Based on the Food and Drug…

Abbott Results Feb 2011 12.6% serious AE View details

Phase 3 N=186 Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension

Hypertension

Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study — -3.12 mmHg

Novartis Results Feb 2011 0.8% serious AE View details

Phase 3 N=193 Psychological Support for Patients With an Implantable Cardioverter Defibrillator

Anxiety · Depression

Primary: Hospital Anxiety and Depression Scale - Depression Scale at Baseline — 4.70; 7.47; 5.35; 4.12 units on a scale

University Health Network, Toronto Results Jan 2011 4.2% serious AE View details

Phase 3 N=63 Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)

Human Experimentation

Primary: Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 7…

Bayer Results Jan 2011 0.5% serious AE View details

Phase 3 N=108 A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis

Migraine

Primary: Pain Relief (PR) — 105; 21; 88; 72 Attacks — p=<0.001

Organon and Co Results Jan 2011 0.0% serious AE View details

Phase 3 N=1,357 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

Influenza

Primary: Antibody Responses According to the Hemagglutinin Inhibition (HI) Assay After the First and Second Vaccinations — 11; 9; 13; 11 percentage of subjects

Novartis Vaccines Results Jan 2011 1.8% serious AE View details